FDA Commissioner Stephen Hahn, MD, was fresh from a controversy over the authorization for emergency use of restorative plasma to treat COVID-19 when he made waves again, this time promising on Twitter that the agency would review coronavirus vaccines for the elections of November. And Pfizer executives seem to be …
Read More »
Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that does not necessarily mean it has the brightest future of all. The high possibility of multiple emergency authorizations for coronavirus vaccines towards the end of the year speaks to a lot of competition – …
Read More »
Text size Dreamstime Older adults who participated in Moderna‘s Phase 1 trial of its Covid-19 vaccine responded just as well as younger adults, according to data, the biotech company presented Wednesday morning to a key Centers for Disease Control and Prevention Advisory panel. This is important because Covid-19 is not …
Read More »
Text size Data from BioNTech and Pfizer were particularly promising. Jeenah Moon / Getty Images After a hiatus from a late summer break, the news of a Covid-19 vaccine is heating up again as a handful of leading programs are rapidly moving to a decisive phase. Reports from several companies …
Read More »
Pfizer (PFE) – Get report and its German partner BioNTech (BNTX) – Get report were increased in premarth trade Friday after the companies said their Covid-19 vaccine candidate would pass tests in the final stage. The companies said the vaccine was “well tolerated with mild to moderate fever in less …
Read More »